Takeda Pharmaceuticals has signed a multiyear deal with Iambic Therapeutics worth up to $1.7 billion, focusing on leveraging AI for drug discovery in oncology, gastrointestinal, and inflammatory diseases. Iambic CEO Tom Miller emphasized that their platform demonstrates real effectiveness through clinical validation, moving beyond AI hype. The partnership aims to enhance Takeda’s R&D efforts, highlighting its shift in strategy towards smaller, more targeted drug modalities. This collaboration builds on Iambic’s existing partnerships and underscores the growing importance of AI in pharmaceuticals, following recent similar agreements in the industry.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fiercebiotech.com/biotech/takeda-inks-17b-ai-discovery-deal-iambic-therapeutics
